Page last updated: 2024-09-04

canertinib and Leukemia, Lymphocytic, T Cell

canertinib has been researched along with Leukemia, Lymphocytic, T Cell in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gréen, A; Gréen, H; Hallbeck, AL; Holmlund, B; Jönsson, JI; Severinsson, EA; Trinks, C; Walz, TM1

Other Studies

1 other study(ies) available for canertinib and Leukemia, Lymphocytic, T Cell

ArticleYear
The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells.
    Biochemical and biophysical research communications, 2011, Jul-08, Volume: 410, Issue:3

    Topics: Apoptosis; Caspases; Humans; Jurkat Cells; Leukemia, T-Cell; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Receptors, Antigen, T-Cell; ZAP-70 Protein-Tyrosine Kinase

2011